The University Of Texas Health Science Center At San Antonio

The Phase 4 CATALYST trial showed mifepristone (Korlym) significantly improved HbA1c in patients with hypercortisolism and difficult-to-control type 2 diabetes, with a placebo-adjusted reduction of 1.32% (P < .0001). The trial, the largest to evaluate hypercortisolism prevalence in such patients, found it present in 23.8% of participants. Mifepristone, a cortisol receptor blocker, demonstrated safety consistent with its label.

UT Health San Antonio Multispecialty and Research Hospital integrates pioneering science and compassionate care, offering comprehensive patient services and advanced clinical research. The facility, designed to support clinical, educational, and research missions, prioritizes patient well-being and includes a protective environment unit for long-term care. Anticipating accreditation in spring 2025, the hospital aims to advance patient care through innovative technologies and treatments, particularly in cancer research and complex diseases affecting the South Texas community.

A new neuroimaging marker, peak-width of skeletonized mean diffusivity (PSMD), related to cerebral small vessel disease, may identify dementia risk in clinical trials. The study, led by UT Health San Antonio, found PSMD efficiently processes brain images in multi-site dementia studies and is associated with lower general cognition. PSMD's non-invasive, automated, fast, and reliable nature makes it ideal for clinical trial use.

UT Health San Antonio ranks in top 5% globally for Clinical Medicine and top 12% overall in U.S. News & World Report’s 2024-2025 Best Global Universities. The university, with $413 million annual research portfolio, is a leader in neurodegenerative diseases, cancer, and mental health research, and is the sixth fastest-growing institution in North America for research output.

Advanced bioengineering strategies aim to address corneal failure by developing bioartificial corneas, addressing the global shortage of human donors. The review explores the structural anatomy of the human cornea, corneal pathologies, current treatments, and emerging strategies in corneal tissue engineering, including cell-free, cell-based, and scaffold-based approaches.

Kind Pharmaceutical's AND017 receives FDA Orphan Drug Designation for Sickle Cell Disease, aiming to treat anemia in chronic kidney disease and other conditions. The designation highlights the urgent need for new therapies and Kind's innovation capability.

Doug E. Frantz appointed vice chancellor for innovation and commercialization at Washington University in St. Louis, effective Jan. 1. Frantz, currently at The University of Texas at San Antonio, will also be a professor at WashU Medicine. He will lead efforts to translate university discoveries into commercial opportunities, overseeing various innovation and commercialization initiatives.

In 2024, the FDA approved dupilumab (Dupixent) as the first biologic for COPD, offering new treatment options. Dupilumab, approved for adults with uncontrolled COPD and an eosinophilic phenotype, demonstrated significant reductions in COPD exacerbations and improvements in lung function in phase 3 trials BOREAS and NOTUS.